Anbio Biotechnology (NNNN) Non-Current Assets (2023 - 2024)
Anbio Biotechnology's (NNNN) quarterly Non-Current Assets came in at $387440.0 in Q4 2024, up 523.53% year-on-year from $62137.0 in Q1 2024, and up 523.53% on a QoQ basis from $62137.0 in Q4 2023.
Anbio Biotechnology (NNNN) Non-Current Assets (2023 - 2024) Analysis & Trends
Anbio Biotechnology (NNNN) has 2 years of Non-Current Assets data on file, last reported at $387440.0 in Q4 2024.
- On a quarterly basis, Non-Current Assets rose 523.53% year-over-year to $387440.0 in Q4 2024; TTM through Dec 2025 was $449577.0, a N/A change from a year earlier, with the FY2024 full-year figure at $387440.0, up 523.53% from the prior year.
- Non-Current Assets for Q4 2024 stood at $387440.0, up from $62137.0 in the prior quarter.
- Over the last five years, Non-Current Assets for NNNN reached as high as $387440.0 in Q4 2024 and fell as low as $62137.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alcon | 32,734,969.19 Bn | 32,734,967.53 Bn | 1.53 Bn | 25.00 Bn |
| 2 | Intuitive Surgical | 117.50 Bn | 112.41 Bn | 1.96 Bn | 11.33 Bn |
| 3 | Becton Dickinson | 42.93 Bn | 42.11 Bn | 2.15 Bn | 42.82 Bn |
| 4 | Medline | 30.82 Bn | 36.66 Bn | 1.84 Bn | 27.83 Bn |
| 5 | Resmed | 27.90 Bn | 26.23 Bn | 890.98 Mn | 4.72 Bn |
| 6 | West Pharmaceutical Services | 26.76 Bn | 26.23 Bn | 329.20 Mn | 2.27 Bn |
| 7 | Cooper Companies | 15.30 Bn | 15.16 Bn | 735.40 Mn | 10.18 Bn |
| 8 | Solventum | 13.46 Bn | 12.90 Bn | 1.10 Bn | 10.51 Bn |
| 9 | Align Technology | 12.02 Bn | 10.96 Bn | 736.59 Mn | 3.66 Bn |
| 10 | Anbio Biotechnology | 425.37 Mn | 413.46 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 387,440.00 |
| Dec 31, 2023 | 62,137.00 |